Impact of natural menopause on multiple sclerosis: a multicentre studyDamiano Baroncini, Mauro Zaffaroni, Marco Ronzoni et al.|Journal of Neurology Neurosurgery & Psychiatry|2019Cited by 70
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Marta Simone et al.|JAMA Neurology|2021Cited by 62
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara Grazia Chisari, Francesco Corea, Giancarlo Comi et al.|Journal of Neurology|2021Cited by 15
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 10
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7